Bevacizumab對人視網(wǎng)膜色素上皮細胞纖維化相關(guān)炎癥因子表達的影響.pdf

1、分類號：R774 密級：UDC：617 學校代碼：11065碩士學位論文Bevacizumab 對人視網(wǎng)膜色素上皮細胞纖維化相關(guān)炎癥因子表達的影響對人視網(wǎng)膜色素上皮細胞纖維化相關(guān)炎癥因子表達的影響儲三軍指 導 教 師 徐海峰學科專業(yè)名稱 眼科學論文答辯日期 2015 年 5 月 22 日AbstractPurpose:To investigate the effect of anti-vascular epithelial growth

2、 factor (VEGF) agents onthe expressions of fibrosis-related inflammatory mediators under normoxic and hypoxicconditions, and to further clarify the mechanism of fibrosis after the treatment ofanti-VEGF.Methods:ARPE-19 ce

3、lls were incubated under normoxic and hypoxic conditions. For hypoxiatreatment, CoCl2 at 200μmol/L was added to the media. ARPE-19 cells were cultured anddivided into 4 groups: ①normal control group: conventional culture

4、. ②bevacizumabgroup: bevacizumab at 0.25mg/ml was added to the media. ③hypoxia group: CoCl2 at200μmol/L was added to the media. ④ hypoxia + bevacizumab group: CoCl2 at200μmol/L and bevacizumab at 0.25mg/ml were added to

5、the media. The secretion ofinterleukin (IL)-1β, IL-6， IL-8, tumor necrosis factor (TNF)-α were evaluated by real-timePCR and ELISA at 6 h, 12 h, 24 h and 48 h.ResultsBoth mRNA and protein levels of IL-1β, IL-6 and IL-8 i

6、n bevacizumab group werehigher than control group at 4 time points, the difference was statistically significant,while the expression of TNF-α gene and protein increased significantly only at 24h and48h (p <0.05). In

7、hypoxia conditions, bevacizumab significantly increased the secretionof IL-1β, IL-6, IL-8, and TNF-α at 6h, 12h, 24h and 48h(p <0.05). IL-1 β, IL-8, andTNF-α peaked at 24h, and IL-6 peaked at 12h after the treatment o

8、f bevacizumab underboth conditions.ConclusionsTreatment of ARPE-19 cells with bevacizumab can significantly increase thesecretion of fibrosis-related inflammatory mediators under normoxic and hypoxicconditions. Inflammat

9、ory factors may be involved in the process of fibrosis after VEGFtreatment, the up regulation expression of inflammatory factors induced by anti-VEGFdrugs may promote the fibrosis process.Keywords: bevacizumab; fibrosis;